Payment overview · 2025
General Payments
$20.45
1 reported records · 1 companies
Healthcare provider profile · identity verified
Mark A Deloach, MD
Allopathic & Osteopathic Physicians|Family Medicine · BAY SPRINGS, MS · NPI 1679681894
Verified facts
What the public records show
CMS Open Payments records show Mark A Deloach, MD received $20.45 in general payments during 2025 across 1 reported records.
Novo Nordisk Inc accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $20.45 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $20.45 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $20.45 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 346 | 104 |
| Amlodipine Besylate | Amlodipine Besylate | 326 | 115 |
| Gabapentin | Gabapentin | 291 | 80 |
| Potassium Chloride | Potassium Chloride | 257 | 56 |
| Pantoprazole Sodium | Pantoprazole Sodium | 213 | 59 |
| Atorvastatin Calcium | Atorvastatin Calcium | 206 | 73 |
| Furosemide | Furosemide | 202 | 61 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 187 | 52 |
| Omeprazole | Omeprazole | 159 | 56 |
| Carvedilol | Carvedilol | 136 | 45 |
| Sertraline Hcl | Sertraline Hcl | 136 | 32 |
| Eliquis | Apixaban | 135 | 31 |
| Trazodone Hcl | Trazodone Hcl | 135 | 41 |
| Metoprolol Succinate | Metoprolol Succinate | 119 | 43 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 114 | 50 |
| Losartan Potassium | Losartan Potassium | 113 | 34 |
| Duloxetine Hcl | Duloxetine Hcl | 112 | 25 |
| Memantine Hcl | Memantine Hcl | 109 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 108 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 108 | 27 |
| Pregabalin | Pregabalin | 104 | 18 |
| Lisinopril | Lisinopril | 103 | 38 |
| Montelukast Sodium | Montelukast Sodium | 101 | 45 |
| Doxycycline Hyclate | Doxycycline Hyclate | 99 | 88 |
| Tamsulosin Hcl | Tamsulosin Hcl | 98 | 31 |
| Famotidine | Famotidine | 96 | 26 |
| Glimepiride | Glimepiride | 96 | 48 |
| Escitalopram Oxalate | Escitalopram Oxalate | 90 | 28 |
| Tramadol Hcl | Tramadol Hcl | 88 | 31 |
| Metformin Hcl | Metformin Hcl | 87 | 37 |
| Prednisone | Prednisone | 86 | 71 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 81 | 14 |
| Donepezil Hcl | Donepezil Hcl | 80 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 77 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 75 | 23 |
| Ropinirole Hcl | Ropinirole Hcl | 63 | 11 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 61 | suppressed |
| Meloxicam | Meloxicam | 61 | 31 |
| Fluticasone Propionate | Fluticasone Propionate | 60 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 59 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 58 | 18 |
| Allopurinol | Allopurinol | 56 | 18 |
| Levofloxacin | Levofloxacin | 56 | 42 |
| Aripiprazole | Aripiprazole | 54 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 54 | 18 |
| Mirtazapine | Mirtazapine | 54 | 12 |
| Jardiance | Empagliflozin | 53 | 19 |
| Fluconazole | Fluconazole | 52 | 32 |
| Hydrochlorothiazide | Hydrochlorothiazide | 52 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 51 | 17 |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 50 | suppressed |
| Lactulose | Lactulose | 50 | 14 |
| Risperidone | Risperidone | 50 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 49 | 33 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 48 | 14 |
| Baclofen | Baclofen | 47 | 11 |
| Buspirone Hcl | Buspirone Hcl | 46 | 14 |
| Cefuroxime | Cefuroxime Axetil | 46 | 40 |
| Alprazolam | Alprazolam | 45 | 17 |
| Pioglitazone Hcl | Pioglitazone Hcl | 45 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 44 | 13 |
| Irbesartan | Irbesartan | 44 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 44 | 26 |
| Spironolactone | Spironolactone | 44 | 14 |
| Celecoxib | Celecoxib | 43 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 43 | 16 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 43 | 13 |
| Trulicity | Dulaglutide | 43 | suppressed |
| Fentanyl | Fentanyl | 42 | 12 |
| Levetiracetam | Levetiracetam | 42 | suppressed |
| Lorazepam | Lorazepam | 42 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 42 | 14 |
| Temazepam | Temazepam | 42 | 11 |
| Valsartan | Valsartan | 40 | 20 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 39 | 32 |
| Ozempic | Semaglutide | 37 | suppressed |
| Synthroid | Levothyroxine Sodium | 37 | suppressed |
| Nystatin | Nystatin | 36 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 35 | suppressed |
| Xarelto | Rivaroxaban | 35 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 34 | 16 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 34 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 33 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 31 | 11 |
| Methocarbamol | Methocarbamol | 31 | 18 |
| Simvastatin | Simvastatin | 31 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 30 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Finasteride | Finasteride | 29 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 29 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 29 | 17 |
| Alendronate Sodium | Alendronate Sodium | 28 | suppressed |
| Clonazepam | Clonazepam | 28 | suppressed |
| Jantoven | Warfarin Sodium | 28 | suppressed |
| Loperamide | Loperamide Hcl | 28 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 28 | 11 |
| Bupropion Xl | Bupropion Hcl | 27 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 27 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 26 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 26 | suppressed |
| Ezetimibe | Ezetimibe | 26 | 13 |
| Linzess | Linaclotide | 26 | suppressed |
| Myrbetriq | Mirabegron | 26 | suppressed |
| Methimazole | Methimazole | 25 | suppressed |
| Eszopiclone | Eszopiclone | 24 | suppressed |
| Mupirocin | Mupirocin | 23 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 23 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 22 |
| Azithromycin | Azithromycin | 22 | 20 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 22 | 14 |
| Rivastigmine | Rivastigmine Tartrate | 22 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 21 | 12 |
| Clindamycin Hcl | Clindamycin Hcl | 21 | 21 |
| Droxidopa | Droxidopa | 21 | suppressed |
| Olanzapine | Olanzapine | 21 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 21 | 11 |
| Creon | Lipase/Protease/Amylase | 20 | suppressed |
| Diazepam | Diazepam | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 19 | 14 |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Estradiol | Estradiol | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | 14 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 17 | 11 |
| Megestrol Acetate | Megestrol Acetate | 17 | suppressed |
| Entacapone | Entacapone | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | suppressed |
| Latanoprost | Latanoprost | 15 | suppressed |
| Novolin R | Insulin Regular, Human | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Rivastigmine | Rivastigmine | 15 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | 12 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 14 | suppressed |
| Atenolol | Atenolol | 13 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Otezla | Apremilast | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Mesalamine | Mesalamine | 12 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 12 | suppressed |
| Cephalexin | Cephalexin | 11 | 11 |
| Combigan | Brimonidine Tartrate/Timolol | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Lumigan | Bimatoprost | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $20.45 · 1 records | Novo Nordisk Inc | Wegovy | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error